Penumbra, Inc. (NYSE:PEN) Receives Average Recommendation of “Hold” from Brokerages

Posted by on Aug 2nd, 2026

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) have earned a consensus recommendation of “Hold” from the seventeen analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $367.0714.

Several research firms recently issued reports on PEN. Wall Street Zen upgraded Penumbra to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Friday, July 17th. Zacks Research lowered Penumbra from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Finally, Evercore reissued an “outperform” rating and issued a $320.00 target price on shares of Penumbra in a research note on Monday, July 6th.

Read Our Latest Analysis on Penumbra

Hedge Funds Weigh In On Penumbra

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PEN. SG Americas Securities LLC boosted its stake in Penumbra by 144.4% in the 4th quarter. SG Americas Securities LLC now owns 11,111 shares of the company’s stock valued at $3,455,000 after purchasing an additional 6,564 shares during the period. Stephens Investment Management Group LLC acquired a new stake in shares of Penumbra during the fourth quarter worth $37,563,000. New York Life Investment Management LLC acquired a new stake in shares of Penumbra during the fourth quarter worth $999,000. Simplify Asset Management Inc. boosted its position in shares of Penumbra by 89.7% in the fourth quarter. Simplify Asset Management Inc. now owns 15,827 shares of the company’s stock valued at $4,921,000 after acquiring an additional 7,485 shares during the period. Finally, SBI Okasan Asset Management Co.Ltd. bought a new stake in shares of Penumbra in the fourth quarter valued at about $2,091,000. 88.88% of the stock is owned by institutional investors.

Penumbra Price Performance

Shares of PEN opened at $321.40 on Friday. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. Penumbra has a twelve month low of $221.26 and a twelve month high of $362.41. The stock has a market capitalization of $12.64 billion, a P/E ratio of 78.97, a P/E/G ratio of 1.99 and a beta of 0.70. The company has a 50 day moving average of $318.75 and a 200-day moving average of $330.03.

Penumbra (NYSE:PEN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.88 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). Penumbra had a return on equity of 10.70% and a net margin of 10.67%.The business had revenue of $390.05 million during the quarter, compared to the consensus estimate of $389.64 million. During the same period in the prior year, the firm earned $0.86 EPS. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. As a group, equities research analysts forecast that Penumbra will post 5.02 EPS for the current fiscal year.

About Penumbra

(Get Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

See Also

Analyst Recommendations for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.